Pharmaxis sells Bronchitol rights in Russia and completes placement
Date Time Pharmaxis sells Bronchitol rights in Russia and completes placement Australian company Pharmaxis has sold Russian distribution rights to cystic fibrosis therapy BRONCHITOL (mannitol) and completed a $4.4 million placement to institutional investors. BRONCHITOL was discovered and developed in Australia. Pharmaxis manufactures the medicine at its facility in Sydney. The company has announced the sale of BRONCHITOL distribution rights in Russia to Turkish company GEN İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for A$2 million. Pharmaxis said 70 per cent of the A$2 million fe...